157 related articles for article (PubMed ID: 7137396)
1. Intensive treatment with haloperidol of treatment-resistant chronic schizophrenic patients.
Hollister LE; Kim DY
Am J Psychiatry; 1982 Nov; 139(11):1466-8. PubMed ID: 7137396
[TBL] [Abstract][Full Text] [Related]
2. RBC and plasma levels of haloperidol and clinical response in schizophrenia.
Smith RC; Vroulis G; Shvartsburd A; Allen R; Lewis N; Schoolar JC; Chojnacki M; Johnson R
Am J Psychiatry; 1982 Aug; 139(8):1054-6. PubMed ID: 7091432
[TBL] [Abstract][Full Text] [Related]
3. The relationship between plasma haloperidol concentrations and clinical results.
Palao DJ; Araúxo A; Haro JM; Brunet M; Bernardo M
Arch Gen Psychiatry; 1996 Dec; 53(12):1167-9. PubMed ID: 8956684
[No Abstract] [Full Text] [Related]
4. Haloperidol plasma levels and dose optimization.
Coryell W; Miller DD; Perry PJ
Am J Psychiatry; 1998 Jan; 155(1):48-53. PubMed ID: 9433338
[TBL] [Abstract][Full Text] [Related]
5. Plasma clozapine and haloperidol concentrations in adolescents with childhood-onset schizophrenia: association with response.
Piscitelli SC; Frazier JA; McKenna K; Albus KE; Grothe DR; Gordon CT; Rapoport JL
J Clin Psychiatry; 1994 Sep; 55 Suppl B():94-7. PubMed ID: 7961584
[TBL] [Abstract][Full Text] [Related]
6. Haloperidol plasma levels and clinical response: a therapeutic window relationship.
Van Putten T; Marder SR; Mintz J; Poland RE
Am J Psychiatry; 1992 Apr; 149(4):500-5. PubMed ID: 1554036
[TBL] [Abstract][Full Text] [Related]
7. Relationship of serum haloperidol levels to clinical response in schizophrenic patients.
Magliozzi JR; Hollister LE; Arnold KV; Earle GM
Am J Psychiatry; 1981 Mar; 138(3):365-7. PubMed ID: 7468835
[TBL] [Abstract][Full Text] [Related]
8. Effects of repeated drug holidays on serum haloperidol concentrations, psychiatric symptoms, and movement disorders in schizophrenic patients.
Newton JE; Cannon DJ; Couch L; Fody EP; McMillan DE; Metzer WS; Paige SR; Reid GM; Summers BN
J Clin Psychiatry; 1989 Apr; 50(4):132-5. PubMed ID: 2925601
[TBL] [Abstract][Full Text] [Related]
9. An open trial of buspirone added to neuroleptics in schizophrenic patients.
Goff DC; Midha KK; Brotman AW; McCormick S; Waites M; Amico ET
J Clin Psychopharmacol; 1991 Jun; 11(3):193-7. PubMed ID: 2066458
[TBL] [Abstract][Full Text] [Related]
10. The Dose Reduction in Schizophrenia (DORIS) Study: a final report.
Hirschowitz J; Hitzemann R; Piscani K; Burr G; Frecska E; Culliton D; Mann M; Curtis C
Schizophr Res; 1997 Jan; 23(1):31-43. PubMed ID: 9050126
[TBL] [Abstract][Full Text] [Related]
11. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
[TBL] [Abstract][Full Text] [Related]
12. Clinical response and plasma haloperidol levels in chronic and subchronic schizophrenia.
Santos JL; Cabranes JA; Vazquez C; Fuentenebro F; Almoguera I; Ramos JA
Biol Psychiatry; 1989 Aug; 26(4):381-8. PubMed ID: 2669981
[TBL] [Abstract][Full Text] [Related]
13. The relationship of haloperidol concentrations to therapeutic response.
Perry PJ; Pfohl BM; Kelly MW
J Clin Psychopharmacol; 1988 Feb; 8(1):38-43. PubMed ID: 3350997
[TBL] [Abstract][Full Text] [Related]
14. Haloperidol blood levels and effects in schizophrenia and schizoaffective disorder: a progress report.
Volavka J; Cooper TB; Meisner M; Bitter I; Czobor P; Jaeger J
Psychopharmacol Bull; 1990; 26(1):13-7. PubMed ID: 2371368
[TBL] [Abstract][Full Text] [Related]
15. Haloperidol: therapeutic window in schizophrenia.
Palao DJ; Arauxo A; Brunet M; Bernardo M; Haro JM; Ferrer J; Gonzalez-Monclus E
J Clin Psychopharmacol; 1994 Oct; 14(5):303-10. PubMed ID: 7806684
[TBL] [Abstract][Full Text] [Related]
16. The interpretation of plasma haloperidol concentrations.
Kirch DG; Bigelow LB; Wyatt RJ
Arch Gen Psychiatry; 1985 Aug; 42(8):838-40. PubMed ID: 4015329
[No Abstract] [Full Text] [Related]
17. Comparison of haloperidol plasma concentrations between twice-a-day and once-a-day dosing in Chinese schizophrenic patients.
Lin SK; Chen CH; Chang WH
J Formos Med Assoc; 1993 Sep; 92(9):832-4. PubMed ID: 7904867
[TBL] [Abstract][Full Text] [Related]
18. Serum haloperidol concentration and clinical response in schizophrenia.
Kirch DG; Bigelow LB; Korpi ER; Wagner RL; Zalcman S; Wyatt RJ
Schizophr Bull; 1988; 14(2):283-9. PubMed ID: 3201181
[TBL] [Abstract][Full Text] [Related]
19. Plasma reduced haloperidol/haloperidol ratios in schizophrenic patients treated with high dosages of haloperidol.
Chang WH; Shieh YS; Liu HC; Jann MW; Chien CP
Eur Neuropsychopharmacol; 1994 Jun; 4(2):119-26. PubMed ID: 7919941
[TBL] [Abstract][Full Text] [Related]
20. A longitudinal assessment of haloperidol doses and serum concentrations in Asian and Caucasian schizophrenic patients.
Lin KM; Poland RE; Nuccio I; Matsuda K; Hathuc N; Su TP; Fu P
Am J Psychiatry; 1989 Oct; 146(10):1307-11. PubMed ID: 2782476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]